A Single-centre Study of COVID-19 Antibody.
J Coll Physicians Surg Pak
; 31(1): S55-S56, 2021 Jan.
Article
in English
| MEDLINE | ID: covidwho-1498351
ABSTRACT
ABSTARCT Four hundred and fifty-three SARS CoV-2 antibodies tests were conducted using Roche Elecsys® Anti SARS CoV-2 kits (detecting total antibodies) between June 13 to July 8, 2020 (25 days) on Cobas® e411 automatic analyser, based on electrochemiluminescence immunoassay (ECLIA) principle. Samples were collected from walk-in patients at our facility. Among them, 2 (0.4%) were found equivocal, 289 (63.8%) were found reactive, while 162 (35.8%) were found non-reactive. Moreover, reactive (symptomatic) cases were 262 (57.8%), reactive (asymptomatic) were 27 (6.0%), non-reactive (symptomatic) were 34 (7.5%), while non-reactive (asymptomatic) were 128 (28.3%). Most common symptom was fever, found in 262 (87.9%) individuals, followed by dry cough 146 (49.0%). Most number of reactive cases, i.e. 110 (42.6%) were those who got themselves tested between 15-21 days after onset of first symptom. Key Words COVID-19, Coronavirus, Antibodies testing.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Diagnostic study
Limits:
Humans
Language:
English
Journal:
J Coll Physicians Surg Pak
Journal subject:
Medicine
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS